High-resolution steady state magnetic resonance angiography of the carotid arteries: Are intravascular agents necessary?: Feasibility and preliminary experience with gadobenate dimeglumine

Investigative Radiology

Volumn 44, Issue 12, 2009, Pages 784-792

  Anzidei, Michele ^a   Napoli, Alessandro ^a   Marincola, Beatrice Cavallo ^a   Kirchin, Miles A ^b   Neira, Cristina ^b   Geiger, Daniel ^a   Zaccagna, Fulvio ^a   Catalano, Carlo ^a   Passariello, Roberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Bracco Imaging SpA   (Italy)

Author keywords

Carotid arteries; Contrast enhanced MR angiography; Gadobenate dimeglumine; Intravascular contrast enhancement; Vascular disease

Indexed keywords

GADOBENATE DIMEGLUMINE;

ADULT; AGED; ARTICLE; CAROTID ARTERY; CAROTID ARTERY OBSTRUCTION; CLINICAL ARTICLE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIGITAL SUBTRACTION ANGIOGRAPHY; FEMALE; HUMAN; IMAGE QUALITY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; PATIENT CARE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING;

EID: 73349126747     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181bfe38a     Document Type: Article

References (45)

1. Chappell FM, Wardlaw JM, Young GR, et al. Carotid artery stenosis: accuracy of noninvasive tests-individual patient data meta-analysis. Radiology. 2009;251:493-502.
2. Hartmann M, Wiethoff AJ, Hentrich HR, et al. Initial imaging recommendations for Vasovist angiography. Eur Radiol. 2006;16(suppl 2):B15-B23.
3. Bluemke DA, Stillman AE, Bis KG, et al. Carotid MR angiography: phase II study of safety and efficacy for MS-325. Radiology. 2001;219:114-122.
4. Anzidei M, Napoli A, Cavallo Marincola B, et al. Gadofosveset-enhanced MR Angiography of carotid arteries: does steady-state imaging improve accuracy of first-pass imaging? Comparison with selective digital subtraction angiography. Radiology. 2009;251:457-466.
5. Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine. Acad Radiol. 1999;6:282-291.
6. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006;1:128-137.
7. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging. 2003;14:426-435.
8. Kirchin MA, Pirovano G, Venetianer C, et al. Safety assessment of gadobenate dimeglumine (Multihance): extended clinical experience from phase I studies to postmarketing surveillance. J Magn Reson Imaging. 2001;14:281-294.
9. Shellock FG, Parker JR, Venetianer C, et al. Safety of gadobenate dimeglumine: summary of findings from clinical studies and post-marketing surveillance. Invest Radiol. 2006;41:500-509.
10. Shellock FG, Parker JR, Pirovano G, et al. Safety characteristics of gado benate dimeglumine: clinical experience from intra and interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging. 2006;24:1378-1385.
11. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40:715-724.
12. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla [erratum in Invest Radiol. 2006;41:859]. Invest Radiol. 2006;41:213-221.
13. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol. 2006;41:222-228.
14. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol. 1997;32:780-796.
15. Bleicher AG, Kanal E. A serial dilution study of gadolinium-based MR imaging agents. Am JNeuroradiol. 2008;29:668-673.
16. Yrjana SK, Vaara T, Karttunen A, et al. Pulse repetition time and contrast enhancement: simulation study of Gd-BOPTA and conventional contrast agent at different field strengths. Invest Radiol. 2008;43:267-275.
17. Volk M, Strotzer M, Lenhart M, et al. Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. Radiology. 2001;220:484-488.
18. Knopp MV, Giesel FL, von Tengg-Kobligk H, et al. Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging. 2003;17:694-702.
19. Wyttenbach R, Gianella S, Alerci M, et al. Prospective Blinded Evaluation of Gd-DOTA versus Gd-BOPTA-enhanced peripheral MR angiography, as compared with digital subtraction angiography. Radiology. 2003;227:261-269.
20. Prokop M, Schneider G, Vanzulli A, et al. Contrast-enhanced MR angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2005; 234:399-408.
21. Pediconi F, Fraioli F, Catalano C, et al. Gadobenate dimeglumine (Gd-BOPTA) vs. gadopentetate dimeglumine (Gd-DTPA) for contrast-enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio. Radiol Med (Torino). 2003;106:87-93.
22. Bultmann E, Erb G, Kirchin MA, et al. Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MR angiography of the supraaortic vessels at 3 Tesla. Invest Radiol. 2008;2008:43:695-702.
23. Anzalone N, Scomazzoni F, Castellano R, et al. Carotid artery stenosis: intra-individual correlations of unenhanced MR angiography, and digital subtraction angiography versus rotational angiography for detection and grading. Radiology. 2005;236:204-221.
24. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445-453.
25. Nikolaou K, Kramer H, Grosse C, et al. High-spatial-resolution multistation MR angiography with parallel imaging and blood pool contrast agent: initial experience. Radiology. 2006;241:861-872.
26. Lauffer RB, Parmelee DJ, Dunham SU, et al. Gadofosveset: albumin-targeted contrast agent for MR angiography. Radiology. 1998;207:529-538.
27. Caravan P, Cloutier NJ, Greenfield MT, et al. The interaction of gadofosveset with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc. 2002;124:3152-3162.
28. Banci L, Bertini I, Luchinat C. Nuclear and Electron Relaxation. Weinheim, Germany: VCH Verlagsgesellschaft GmbH; 1991:138.
29. Thurnher S, Miller S, Schneider G, et al. Diagnostic performance of gado-benate dimeglumine enhanced MR angiography of the iliofemoral and calf arteries: a large-scale multicenter trial. Am J Roentgenol. 2007;189:1223-1237.
30. Soulez G, Pasowicz M, Benea G, et al. Renal artery stenosis evaluation: diagnostic performance of gadobenate dimeglumine-enhanced MR angiog-raphy-comparison with DSA. Radiology. 2008;247:273-285.
31. Schneider G, Ballarati C, Grazioli L, et al. Gadobenate dimeglumine-en-hanced MR angiography: diagnostic performance of four doses for detection and grading of carotid, renal, and aorto-iliac stenoses compared to digital subtraction angiography. J Magn Reson Imaging. 2007;26:1020-1032.
32. Kroencke TJ, Wasser MN, Pattynama PM, et al. Gadobenate dimeglumine-enhanced magnetic resonance angiography of the abdominal aorta and renal arteries. Am J Roentgenol. 2002;179:1573-1582.
33. Wikström J, Wasser MN, Pattynama PM, et al. Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries. Invest Radiol. 2003;38:504-515.
34. Maravilla KR, Maldjian JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology. 2006;240:389-400.
35. Rowley HA, Scialfa G, Gao PY, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gado-benate dimeglumine versus gadodiamide. Am J Neuroradiol. 2008;29:1684-1691.
36. Rumboldt Z, Rowley HA, Steinberg F, et al. Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglu-mine and gadopentetate dimeglumine in MRI of brain tumors at 3 Tesla. J Magn Reson Imaging. 2009;29:760-767.
37. Pediconi F, Catalano C, Occhiato R, et al. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dime-glumine versus gadopentetate dimeglumine. Radiology. 2005;237:45-56.
38. Pediconi F, Catalano C, Padula S, et al. Contrast-enhanced MR mammogra-phy: improved lesion detection and differentiation with gadobenate dimeglu-mine. Am J Roentgenol. 2008;191:1339-1346.
39. Pediconi F, Catalano C, Roselli A, et al. The challenge of imaging dense breast parenchyma: is magnetic resonance mammography the technique of choice? A comparative study with x-ray mammography and whole-breast ultrasound. Invest Radiol. 2009;44:412-421.
40. Balci NC, Inan N, Anik Y, et al. Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging. Acad Radiol. 2006;13:833-839.
41. Bauner KU, Reiser MF, Huber AM. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine. Invest Radiol. 2009;44:95-104.
42. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephro-genic systemic fibrosis: why radiologists should be concerned. Am J Roent-genol. 2007;188:586-592.
43. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-157.
44. Dawson P. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies. J Magn Reson Imaging. 2008;28:797-804.
45. Lohan DG, Tomasian A, Saleh RS, et al. Ultra-low-dose, time-resolved contrast-enhanced magnetic resonance angiography of the carotid arteries at 3.0 tesla. Invest Radiol. 2009;44:207-217.